摘要
125I是一种重要的医用放射性核素,由于其半衰期较长(T1/2=59.4 d),γ射线能量低、无β辐射,对人体组织产生的辐射损伤小等优点,使其在生物医学、放射免疫体外诊断和近距离植入治疗肿瘤等方面得到了广泛应用。本文简要介绍125I的生产原理、国内外生产工艺研究现状、国内市场需求,并展望125I的生产前景。
Iodine-125(125I)is one of the most attractive and significant radionuclide that is widely used in biomedical,radioimmunoassay in vitro diagnosis and brachytherapy for tumors owing to its favorable nuclear characteristics,including low energy X-ray,noβ-ray,less radiation damage.In this paper,the process and current status of 125I production technology,demand of domestic market and the prospect of 125I were briefly introduced.
作者
李波
罗宁
曾俊杰
吴建荣
贾致军
王磊
孙志中
陈云明
张劲松
LI Bo;LUO Ning;ZENG Junjie;WU Jianrong;JIA Zhijun;WANG Lei;SUN Zhizhong;CHEN Yunming;ZHANG Jingsong(Nuclear Power Institute of China,Chengdu 610213,China;Radioisotope Engineering Technology Research Center of Sichuan,Chengdu 610213,China)
出处
《同位素》
CAS
2020年第6期366-373,共8页
Journal of Isotopes
作者简介
李波(1987-),男,四川泸州人,助理研究员,主要从事同位素技术开发与应用研究。
